Drug profile · INN
gemifloxacin mesylate
GEMIFLOXACIN MESYLATE
gemifloxacin mesylate (GEMIFLOXACIN MESYLATE) is a dna gyrase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — gemifloxacin mesylate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 4
- Data quality
- 0.84
Quick answer
gemifloxacin mesylate (GEMIFLOXACIN MESYLATE) is a dna gyrase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
DNA gyrase inhibitor
Primary target: DNA gyrase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is gemifloxacin mesylate?
gemifloxacin mesylate (GEMIFLOXACIN MESYLATE) is a dna gyrase inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for gemifloxacin mesylate?
GEMIFLOXACIN MESYLATE is a marketed brand name for gemifloxacin mesylate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of gemifloxacin mesylate?
gemifloxacin mesylate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.